ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$99.9M
(+20%)
Cap. Flow
+$40.6M
Cap. Flow
% of AUM
6.81%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
77
Reduced
72
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYRS
176
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $96.8K | 0.02% |
+45,000
| New | +$96.8K |
|
177
Scholar Rock
SRRK
$3.02B
| $96.1K | 0.02% |
12,000
| – | – |
|
178
Liquidia Corp
LQDA
$2.48B
| $92.9K | 0.02% |
+9,285
| New | +$92.9K |
|
179
Nektar Therapeutics
NKTR
$764M
| $88.1K | 0.01% |
+4,517
| New | +$88.1K |
|
180
Establishment Labs
ESTA
$1.13B
| $86.5K | 0.01% |
+2,000
| New | +$86.5K |
|
181
BioMarin Pharmaceuticals
BMRN
$11.1B
| $84.3K | 0.01% |
+1,200
| New | +$84.3K |
|
182
Corbus Pharmaceuticals
CRBP
$121M
| $82.5K | 0.01% |
4,000
-8,000
| -67% | -$165K |
|
183
Rocket Pharmaceuticals
RCKT
$354M
| $79.4K | 0.01% |
4,300
+4,200
| +4,200% | +$77.6K |
|
|
AITR
184
DELISTED
AI TRANSPORTATION ACQUISITION CORP Ordinary shares
AITR
| $78.6K | 0.01% |
+7,500
| New | +$78.6K |
|
|
IMA
185
ImageneBio, Inc. Common Stock
IMA
$89M
| $77.2K | 0.01% |
3,720
-170
| -4% | -$3.53K |
|
186
Applied Therapeutics
APLT
$68.2M
| $74.2K | 0.01% |
8,727
-312,000
| -97% | -$2.65M |
|
|
VIGL
187
DELISTED
Vigil Neuroscience
VIGL
| $73.9K | 0.01% |
+21,737
| New | +$73.9K |
|
|
ITI
188
DELISTED
Iteris, Inc.
ITI
| $71.4K | 0.01% |
+10,000
| New | +$71.4K |
|
189
4D Molecular Therapeutics
FDMT
$340M
| $64.9K | 0.01% |
6,000
+4,000
| +200% | +$43.2K |
|
190
CVS Health
CVS
$93.6B
| $62.9K | 0.01% |
+1,000
| New | +$62.9K |
|
|
PRTC
191
PureTech Health
PRTC
$392M
| $61.8K | 0.01% |
3,000
+2,300
| +329% | +$47.4K |
|
|
GRAL
192
GRAIL, Inc. Common Stock
GRAL
$1.33B
| $60.6K | 0.01% |
4,401
-17,000
| -79% | -$234K |
|
193
West Pharmaceutical
WST
$18B
| $60K | 0.01% |
200
-690
| -78% | -$207K |
|
194
Greenlight Captial
GLRE
$436M
| $59.9K | 0.01% |
4,385
-8,000
| -65% | -$109K |
|
195
argenx
ARGX
$45.9B
| $59.6K | 0.01% |
+110
| New | +$59.6K |
|
196
Organon & Co
OGN
$2.7B
| $59.3K | 0.01% |
3,100
+600
| +24% | +$11.5K |
|
197
TripAdvisor
TRIP
$2.05B
| $58K | 0.01% |
4,000
-18,000
| -82% | -$261K |
|
198
AstraZeneca
AZN
$253B
| $54.5K | 0.01% |
700
+600
| +600% | +$46.7K |
|
199
Axsome Therapeutics
AXSM
$6.25B
| $53.9K | 0.01% |
600
+300
| +100% | +$27K |
|
|
TVRD
200
Tvardi Therapeutics, Inc. Common Stock
TVRD
$292M
| $49.1K | 0.01% |
4,430
| – | – |
|